Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial
D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.
Is BRC Therapeutics opening a new regulatory lane for cannabinoid-based CRPS therapies?
CRPS has no approved U.S. therapy. BRC-002 now has an FDA path, but proof of safety, efficacy, and dosing discipline still lies ahead.
Is Can-Fite BioPharma Ltd. building a differentiated niche in late-line pancreatic cancer therapy
Is Can-Fite BioPharma Ltd. carving a niche in pancreatic cancer? Explore how namodenoson’s Phase 2a data could reshape late-line treatment strategies.
What Orion Corporation’s FDA orphan designation for ODM-212 means for mesothelioma treatment innovation
Discover how Orion Corporation’s ODM-212 orphan drug status could reshape mesothelioma treatment and drive innovation in Hippo pathway targeting.
What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
Discover how SkinJect’s orphan drug bid could reshape Hedgehog-driven cancer treatment. Read what it means for clinicians, regulators, and investors.
Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
Can Ampligen’s Phase 3 push reshape pancreatic cancer treatment? Read how AIM ImmunoTech’s latest clinical progress could change the oncology outlook.
Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Can REYOBIQ improve Plus Therapeutics’ path in pediatric high-grade glioma and ependymoma?
Plus Therapeutics won orphan drug designation for REYOBIQ in pediatric malignant gliomas. Read what it changes for CNS cancer development.
How REYOBIQ’s latest regulatory milestone may reshape the pediatric neuro-oncology landscape
Plus Therapeutics secures orphan designation for REYOBIQ in pediatric malignant gliomas. Read what this means for trials, exclusivity, and market strategy.
Can Abbisko Therapeutics turn irpagratinib into the first approved FGFR4 therapy for hepatocellular carcinoma?
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.